Prevalence and related factors of anemia in HAART-naive HIV positive patients at Gondar University Hospital, Northwest Ethiopia

BMC Hematology

Yitayih Wondimeneh¹  Getachew Ferede¹ 

[1] School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia

关键词: CD4 count;    HAART-naïve;    HIV;    Anaemia;   

Others  :  848418
DOI  :  10.1186/2052-1839-13-8

 received in 2012-09-21, accepted in 2013-08-07,  发布年份 2013

【 摘 要 】

Background

Anaemia is a common complication of infection with the human immunodeficiency virus (HIV) and may have various causes. The aim of this study was to determine the prevalence and related factors of anemia in HAART-naive HIV positive Patients.

Methods

A retrospective study was conducted on HAART naive HIV positive patients at the Gondar University Hospital between September 2011 and August 2012. Socio-demographic and immunohematological (hemoglobin and CD4+ T cells) data were collected carefully from the existing ART logbook and patient follow up cards. Anaemia was defined according to the WHO criteria.

Results

The overall prevalence of anaemia was 138 (35%). Female HAART naive HIV positive patients had significantly (P < 0.05) higher prevalence of anaemia than males (62% Vs 38%). The prevalence of anaemia at different CD4 level was; 6 (4%) with CD4 count greater than 500 cells/μL, 18 (13%) with a CD4 count of 350–500 cells/μL, 37 (27%) with a CD4 count of 200–349 cells/μL, 44 (32%) with a CD4 count of 100–199 cells/μL, 14 (10%) with a CD4 count of 50–99 and 19 (14%) with CD4 count of less than 50 cells/μL.

Conclusions

Our findings showed that one-third of HAART naïve HIV positive patients were anaemic and the increase in prevalence of anaemia with decreased CD4 cell count was statistically significant. Therefore, early diagnosis and treatment of anaemia in these patients are essential.

【 授权许可】

   
2013 Ferede and Wondimeneh; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW: Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998, 91:301-308.
• [2]Shah I, Murthy AK: Aplastic anemia in an HIV infected child. Indian J Pediatr 2005, 72:359-361.
• [3]Belperio PS, Rhew DC: Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004, 116:27-43.
• [4]Atti.li S, Singh V, Rai M, Varma D, AK G: Hematological profile of HIV patients in relation to immune status - a hospital-based cohort from Varanasi, North India. Turk J Hematol 2008, 25:13-19.
• [5]Savarino A, Pescarmona GP, Boelaert JR: Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences. Cell Biochem Funct 1999, 7:279-287.
• [6]Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, et al.: Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. J Acquir Immune Defic Syndr 2005, 39:620-625.
• [7]Lundgren JD, Mocroft A: Anemia and survival in human immunodeficiency virus. Clin Inf Dis 2003, 37:297-303.
• [8]Doukas MA: Human immunodeficiency virus associated anemia. Med Clin North Am 1992, 76:699.
• [9]Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, DArminio Monforte A, Ledergerber B, Lundgren JD: Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999, 13:943-950.
• [10]Semba RD, Martin BK, Kempen JH, Thorne JE, Wu AW: The impact of anemia on energy and physical functioning in individuals with AIDS. Arch Intern Med 2005, 165:2229-2236.
• [11]Semba RD: Iron-deficiency anemia and the cycle of poverty among human immunodeficiency virus-infected women in the inner city. Clin Infect Dis 2003, 37:105-111.
• [12]Evans RH, Scadden DT: Haematological aspects of HIV infection. Baillieres Best Pract Res Clin Haematol 2000, 13:215-230.
• [13]Spivak JL: The blood in systemic disorders. Lancet 2000, 355:1707-12.
• [14]Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A, Spengler U, Sauerbruch T, et al.: Inadequate erythropoietin response to anemia in HIV patients: relationship to serum levels of tumor necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Haematol 1997, 96:235-9.
• [15]Onyekachi I: Maximizing response to erythropoietin in treating HIV-associated anemia. Cleve Clin J Med 2001, 68:643-648.
• [16]Miller MF, Humphrey JH, Iliff PJ, Malaba LC, Mbuya NV, Stoltzfus RJ: Neonatal erythropoiesis and subsequent anemia in HIV-positive and HIV-negative Zimbabwean babies during the first year of life: a longitudinal study. BMC Infect Dis 2006, 6:1. BioMed Central Full Text
• [17]Florence M, Jean Bosco G, Joshua M, Joris D, Jan P: Anemia in Human Immunodeficiency Virus–Infected and Uninfected Women in Rwanda. Am J Trop Med Hyg 2011, 84:456-460.
• [18]Izaks GJ, Westendorp RGJ, Knooks DL: The definition of anaemia in older persons. JAMA 1999, 281:1714-1717.
• [19]Volberding P: The impact of anaemia on quality of life in human immunodeficiency virus infected patients. Clin Infect Dis 2002, 185:110-114.
• [20]Kreuzer KA, Rockstroh JK: Pathogenesis and pathophysiology of anemia in HIV infection. Ann Hematol 1997, 75:179-87.
• [21]Mildvan D, Creagh T, Leitz G: Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: findings of the Anemia Prevalence Study. Curr Med Res Opin 2007, 23:343-55.
• [22]Levine AM, Berhane K, Masri-Lavine L, et al.: Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J acquir Immune defic syndr 2001, 26:28-35.
• [23]Semba RD, Shah N, Klein RS, et al.: Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 2002, 34:260-6.
• [24]Mata-Marin JA, Gaytan-Martinez JE, Martinez-Martinez RE, Arroyo-Anduiza CI, Fuentes-Allen JL, Casarrubias-Ramirez M: Risk factors and correlates for anemia in HIV treatment-naïve infected patients: A cross-sectional analytical study. BMC Res Notes 2010, 3:230. BioMed Central Full Text
• [25]Akinsegun A, Olajumoke O, Titilope A, Adewunmi A, Owolabi D, Mobolaji D, Idris D, Alaba A, Oshunkalu V: Hematologic Abnormalities in Treatment-Naïve HIV Patients. Infect Dis 2010, 3:45-49.
• [26]Owiredu WK, Quaye L, Amidu N, Addai-Mensah O: Prevalence of anaemia and immunological markers among Ghanaian HAART-naïve HIV-patients and those on HAART. Afr Health Sci 2011, 11:2-15.
• [27]Nadler JP, Wills TS, Somboonwit C, Vincent A, Lietz G, Marino K, Naik E, Powers S, Khan N, Almyroudis N, Laatz B: Anaemia prevalence among HIV patients: antiretroviral therapy and other risk factors. Antivir Ther 2003, 8:1.
• [28]Omoregie R, Omokaro EU, Palmer O, Ogefere HO, Egbeobauwaye A, Adeghe JE, Osakue SI, Ihemeje V: Prevalence of anaemia among HIV-infected patients in Benin City, Nigeria. Tanzan J Health Res 2009, 11:1.
• [29]Volberding PA, Dieterich D, Mildvan D, Mitsuyasu R, Saag M: Anemia in HIV inf ection: clinical impact and evidence-based management strategies. Clin Infect Dis 2004, 39:1088-9.
• [30]Coyle TE: Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med clin north am 1997, 81:449-470.
• [31]Hambleton J: Hematologic complications of HIV infection. Oncology 1996, 10:671-680.
• [32]Walker RE, Parker RI, Kovacs JA, et al.: Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi’s sarcoma treated with zidovudine. Ann Intern Med 1988, 108:372-6.
• [33]MariekeJ VDW, Birgit H, et al.: Prevalence, incidence and risk factors of anaemia in HIV-positive and HIV-negative drug users. Addiction 2000, 95:383-392.
• [34]Dikshit B, Wanchu A, Sachdeva RK, et al.: Profile of Hematological Abnormalities in Indian HIV infected Individuals. BMC blood disorder 2009, 9:5. BioMed Central Full Text